Hippocratic AI Expands Life Sciences Operations with Grove AI Acquisition and Strategic Leadership Appointments
核心洞察
Hippocratic AI (搜索) has acquired Grove AI (搜索), a specialist in agentic AI for pharmaceutical R&D and clinical trial operations, to establish a dedicated Life Sciences Division focused on biopharma and medtech applications.
The combined platform has supported over 10 million patient interactions in the past year, with Grove AI (搜索)'s technology automating thousands of manual workflows across clinical research and development.
The company appointed Dr. Ahad Wahid as President of Life Sciences and formed an executive advisory panel featuring former leaders from Gilead Sciences, AbbVie (搜索), Boston Scientific, and the National Cancer Institute.
Hippocratic AI (搜索), the global leader in patient-facing generative AI healthcare agents, has significantly expanded its life sciences operations through the acquisition of Grove AI (搜索) and key strategic appointments. The move establishes the company as a category leader in deploying safe, scalable generative AI across the biopharma and medtech value chain, from R&D and clinical trials to commercialization and post-market patient engagement.
Strategic Acquisition Strengthens Clinical Trial Capabilities
The acquisition of Grove AI (搜索) brings specialized agentic AI technology for pharmaceutical R&D and clinical trial operations to Hippocratic AI (搜索)'s portfolio. Grove AI's platform supported more than 10 million patient interactions over the past year, identifying opportunities to automate and transform thousands of slow, manual workflows across clinical research and development.
"At Grove AI (搜索), we built the leading agentic AI solution for pharma R&D by working directly with clinical teams and patients at scale," said Tran Le, Co-Founder of Grove AI. "By joining Hippocratic AI (搜索), we can build on that foundation and accelerate the delivery of these capabilities to a much broader set of life sciences organizations, combining our innovation with Hippocratic AI's enterprise scale."
The acquisition introduces two cornerstone offerings to Hippocratic AI (搜索)'s life sciences portfolio: AI Agent "Grace (搜索)," an always-on, multilingual AI agent supporting end-to-end patient engagement, recruitment, and follow-up across voice, text, and email; and Grove AI (搜索) PRM™ (Participant Relationship Management), a purpose-built platform orchestrating AI-driven participant interactions with full transparency, human oversight, and regulatory alignment.
Executive Leadership and Advisory Panel Formation
Dr. Ahad Wahid has been appointed as President of Life Sciences, bringing extensive clinical and strategic expertise to the role. A former NHS surgeon and member of the UK General Medical Council's Quality Assurance Board, Dr. Wahid spent a decade as a Partner at Boston Consulting Group (搜索), where he led global AI and healthcare transformation initiatives and advised executive teams at more than 30 leading healthcare organizations.
"Hippocratic AI (搜索) is building what life sciences has been waiting for: generative AI that can scale globally without compromising safety or regulatory integrity," said Dr. Wahid. "My focus is ensuring these technologies are deployed responsibly, measurably, and at enterprise scale so innovation translates into real outcomes for patients and organizations alike."
The company has also established a Life Sciences Executive Advisory Panel featuring seasoned industry leaders: Jim Meyers, former Chief Commercial Officer at Gilead Sciences who led the launch of 24 products including 11 blockbuster brands; Michael Norton, former VP of Global Medical Affairs at AbbVie (搜索) with over 20 years in R&D and medical leadership; David Pierce, former President of MedSurg, Endoscopy, and Urology at Boston Scientific; and Richard Klausner, former Director of the National Cancer Institute and Co-founder of multiple biotechnology companies including Altos Labs (搜索).
Technology Platform and Safety Architecture
Hippocratic AI (搜索)'s generative AI agents are powered by the proprietary Polaris safety architecture (搜索), delivering high-fidelity clinical reasoning and enterprise-grade auditability at scale. The platform is backed by more than 150 million clinical interactions to date and follows the company's recent $126M Series C financing, with a portion of proceeds earmarked for mergers and acquisitions.
"Real impact in the life sciences sector requires deeply specialized models, exhaustive safety testing, and LLM safety architectures built to operate within highly regulated environments," said Munjal Shah, Co-founder and CEO of Hippocratic AI (搜索). "That is why Hippocratic AI has strategically expanded its life sciences leadership."
The combined team is currently collaborating with five of the world's leading global pharmaceutical companies to deploy AI agents for patient and provider engagement at enterprise scale. Grove AI (搜索) was launched in 2024 with $4.9 million in seed funding by ex-Stanford Medicine engineers and has worked with two of the top five pharmaceutical groups.
Strategic Partnership with Boston Consulting Group
Complementing the acquisition, Hippocratic AI (搜索) has entered into a strategic collaboration with Boston Consulting Group (搜索) (BCG) and BCG X to help pharma and medtech clients adopt generative AI solutions aligned with commercial, R&D, and medical affairs goals. The partnership combines BCG's AI transformation leadership with Hippocratic AI's generative AI healthcare agents designed for safety, patient trust, and scale.
"This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI (搜索)'s sophisticated AI agent platform, BCG's strategy and governance expertise, and BCG X's Health Care Commercial AI solution to help clients turn potential into measurable business value," said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X.
The expansion positions Hippocratic AI (搜索) to address the growing demand for AI-powered solutions in life sciences while maintaining the regulatory rigor and safety standards required in highly regulated healthcare environments.